The firms will use Engitix’ extracellular matrix (ECM) discovery platform to develop new therapies for fibrotic liver diseases
News
AbbVie submits Rinvoq for ankylosing spondylitis
In a pivotal Phase II/III study, twice as many patients receiving the drug achieved the primary endpoint of ASAS 40 response at week 14 versus placebo
No increased risk from COVID-19 for healthy pregnant women
Pregnant women were no more likely to suffer severe symptoms of COVID-19 or be ill for longer than those who weren’t pregnant, if otherwise healthy
Novartis’ CML drug hits PhIII targets
Asciminib was superior to bosutinib in inducing a major molecular response
Clinical research cut 87% at peak of pandemic
The model suggests that just 13% of full-time academics would have been available to carry out research during the height of the pandemic
WHF partners with AZ to reduce burden of CV disease
New initiatives will raise public awareness of the burden of heart failure to boost prevention, diagnosis and treatment
AZ kicks off PhI trial of potential COVID-19 therapy
The monoclonal antibody combination is being tested for prevention and treatment of coronavirus
First coronavirus re-infection reported in Hong Kong
A 33-year-old man was infected twice with slightly different strains of coronavirus more than four months apart
Gov unveils fund for follow-on care
The £588-million fund can be used to provide up to six weeks of care and support following hospital discharge
AZ partners with RenalytixAI in chronic disease pact
Parties to adopt multi-phase approach to develop precision medicine strategies to optimize treatment of cardiovascular, renal and metabolic disease
Novartis’ melanoma combo fails in PhIII
The study assessed investigational immunotherapy spartalizumab (PDR001) in combination with targeted therapies Tafinlar and Mekinist
EU nod for Vertex CF therapy Kaftrio
Clearance was based on two global Phase III studies showing statistically significant improvements in lung function
Patient Partnership Index virtual conference to take place October 7
The free event will discuss key insights into achieving impactful patient partnerships and advocacy
US expand use of Janssen’s Darzalex
The approval broadens the drug’s label to include fifth treatment option in the relapsed/refractory multiple myeloma setting
J&J to acquire Momenta for $6.5 billion
The move will expand Janssen’s presence in autoimmune diseases
